Head-to-head · WeighScore
No BS RX vs PreventiveMD
By GLP-1 ScorecardUpdated
Score comparison
No BS RX has the higher recorded score — 82.8/100 to 76.4/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.
Before you choose
Before comparing the headline prices, the No BS RX review and the PreventiveMD review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, No BS RX vs PrideRx and NuuVim vs PreventiveMD compare each of them with another graded program, and the list of alternatives to No BS RX ranks the programs closest to No BS RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the bmiMD review covers one graded close to these two, at 79.2/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | No BS RX | PreventiveMD |
|---|---|---|
| WeighScore | 82.8/100 | 76.4/100 |
| Grade | B− | C |
| Site position | #23 | #53 |
| Semaglutide | $149/mo advertised for standard compounded injection; low-dose priced separately | $75/mo (annual prepay, $900 upfront, compounded) |
| Tirzepatide | $225/mo advertised for standard compounded injection; low-dose priced separately | $97/mo (annual prepay, $1,168 upfront, compounded) |
| Coverage | Confirm program availability for your state | 43 states; excludes DC |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Strengths
- Displays monthly and prepaid amounts by program
- Advertises consultation, medication, shipping and messaging in the compounded plans
- Lists branded Ozempic and Zepbound separately
What to consider
- The $115 headline applies to low-dose programs
- Plans renew automatically at the then-current rate
- Cancellation generally stops future billing without refunding the current period
Strengths
- Names Empower, Drug Crafters and Boudreaux’s New Drug Store as pharmacy choices, subject to state licensing
- Publishes one-, three-, six- and twelve-month compound plans with the same price across doses
- One-month compound plans are $99 for semaglutide and $139 for tirzepatide, including medication, review, supplies and shipping
- Offers branded oral and injectable options through a separate membership model
What to consider
- The $75/$97 headlines require annual prepayment of $900/$1,168; six- and twelve-month plans ship three months at a time
- Brand-name medication costs are additional to the $49 monthly membership
- Excludes AK, AR, MS, NJ, NM, SD, WV and DC; pharmacy-specific restrictions also apply
- Initial review is generally asynchronous within 24–48 hours; renewal cancellation does not automatically refund a prepaid term
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.